The team behind ophthalmology startup Vedere Bio Inc. is launching a new venture — and they’re keeping the name: Vedere Bio II Inc. With $77 million in funding, it’s got a bold mission to restore vision in patients who have gone blind due to genetic mutations affecting the retina.
Read More
